Annexin A5 prevents post-interventional accelerated atherosclerosis development in a dose-dependent fashion in mice

Atherosclerosis

Volumn 221, Issue 2, 2012, Pages 333-340

  Ewing, M M ^a   Karper, J C ^a   Sampietro, M L ^a,b   de Vries, M R ^a   Pettersson, K ^c   Jukema, J W ^a   Quax, P H A ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

^c Athera Biotechnologies   (Sweden)

Author keywords

Annexin A5; Atherosclerosis; Genetics; Inflammation; Restenosis

Indexed keywords

GLUCOSE REGULATED PROTEIN 78; LIPOCORTIN 5;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG BLOOD LEVEL; FOAM CELL; HYPERCHOLESTEROLEMIA; IN VIVO STUDY; LEUKOCYTE ADHERENCE; MACROPHAGE; MOUSE; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RESTENOSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALS; ANNEXIN A5; APOLIPOPROTEINS E; ARTERIAL OCCLUSIVE DISEASES; CASE-CONTROL STUDIES; CHEMOTAXIS, LEUKOCYTE; CONSTRICTION; CONSTRICTION, PATHOLOGIC; CORONARY RESTENOSIS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMORAL ARTERY; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; INJECTIONS, INTRAPERITONEAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NETHERLANDS; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS;

EID: 84858699920     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.01.037     Document Type: Article

References (30)

1. van der Hoeven B.L., Pires N.M., Warda H.M., Oemrawsingh P.V., van Vlijmen B.J., Quax P.H., Schalij M.J., van der Wall E.E., Jukema J.W. Drug-eluting stents: results, promises and problems. Int. J. Cardiol. 2005, 99:9-17.
2. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J Med. 2005, 352:1685-1695.
3. Ross R. Atherosclerosis - an inflammatory disease. N. Engl. J Med. 1999, 340:115-126.
4. Moore K.J., Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell 2011, 145:341-355.
5. Tabas I. Pulling down the plug on atherosclerosis: finding the culprit in your heart. Nat. Med. 2011, 17:791-793.
6. Hotamisligil G.S. Endoplasmic reticulum stress and atherosclerosis. Nat. Med. 2010, 16:396-399.
7. Tabas I. The role of endoplasmic reticulum stress in the progression of atherosclerosis. Circ. Res. 2010, 107:839-850.
8. Andree H.A., Stuart M.C., Hermens W.T., Reutelingsperger C.P., Hemker H.C., Frederik P.M., Willems G.M. Clustering of lipid-bound annexin V may explain its anticoagulant effect. J. Biol. Chem. 1992, 267:17907-17912.
9. Thiagarajan P., Benedict C.R. Inhibition of arterial thrombosis by recombinant annexin V in a rabbit carotid artery injury model. Circulation 1997, 96:2339-2347.
10. van Heerde W.L., Sakariassen K.S., Hemker H.C., Sixma J.J., Reutelingsperger C.P., De Groot P.G. Annexin V inhibits the procoagulant activity of matrices of TNF-stimulated endothelium under blood flow conditions. Arterioscler. Thromb. 1994, 14:824-830.
11. Gerke V., Moss S.E. Annexins: from structure to function. Physiol. Rev. 2002, 82:331-371.
12. van Heerde W.L., Poort S., Reutelingsperger 'van V.C.P., De Groot P.G. Binding of recombinant annexin V to endothelial cells: effect of annexin V binding on endothelial-cell-mediated thrombin formation. Biochem. J. 1994, 302(Pt. 1):305-312.
13. Ravassa S., Bennaghmouch A., Kenis H., Lindhout T., Hackeng T., Narula J., Hofstra L., Reutelingsperger C. Annexin A5 down-regulates surface expression of tissue factor: a novel mechanism of regulating the membrane receptor repertoir. J. Biol. Chem. 2005, 280:6028-6035.
14. Kenis H., Hofstra L., Reutelingsperger C.P. Annexin A5: shifting from a diagnostic towards a therapeutic realm. Cell Mol. Life Sci. 2007, 64:2859-2862.
15. van Genderen H.O., Kenis H., Hofstra L., Narula J., Reutelingsperger C.P. Extracellular annexin A5: functions of phosphatidylserine-binding and two-dimensional crystallization. Biochim. Biophys. Acta 2008, 1783:953-963.
16. Leon C., Nandan D., Lopez M., Moeenrezakhanlou A., Reiner N.E. Annexin V associates with the IFN-gamma receptor and regulates IFN-gamma signaling. J. Immunol. 2006, 176:5934-5942.
17. Kietselaer B.L., Reutelingsperger C.P., Heidendal G.A., Daemen M.J., Mess W.H., Hofstra L., Narula J. Noninvasive detection of plaque instability with use of radiolabeled annexin A5 in patients with carotid-artery atherosclerosis. N. Engl. J Med. 2004, 350:1472-1473.
18. Balasubramanian K., Mirnikjoo B., Schroit A.J. Regulated externalization of phosphatidylserine at the cell surface: implications for apoptosis. J. Biol. Chem. 2007, 282:18357-18364.
19. Boersma H.H., Kietselaer B.L., Stolk L.M., Bennaghmouch A., Hofstra L., Narula J., Heidendal G.A., Reutelingsperger C.P. Past, present, and future of annexin A5: from protein discovery to clinical applications. J. Nucl. Med. 2005, 46:2035-2050.
20. van Tits L.J., van Heerde W.L., van der Vleuten G.M., de Graaf J., Grobbee D.E., van de Vijver L.P., Stalenhoef A.F., Princen H.M. Plasma annexin A5 level relates inversely to the severity of coronary stenosis. Biochem. Biophys. Res. Commun. 2007, 356:674-680.
21. Ravassa S., Gonzalez A., Lopez B., Beaumont J., Querejeta R., Larman M., Diez J. Upregulation of myocardial Annexin A5 in hypertensive heart disease: association with systolic dysfunction. Eur. Heart J. 2007, 28:2785-2791.
22. Peetz D., Hafner G., Blankenberg S., Peivandi A.A., Schweigert R., Brunner K., Dahm M., Rupprecht H.J., Mockel M. Annexin V does not represent a diagnostic alternative to myoglobin for early detection of myocardial infarction. Clin. Lab. 2002, 48:517-523.
23. Ewing M.M., de Vries M.R., Nordzell M., Pettersson K., de Boer H.C., van Zonneveld A.J., Frostegard J., Jukema J.W., Quax P.H. Annexin A5 therapy attenuates vascular inflammation and remodeling and improves endothelial function in mice. Arterioscler. Thromb. Vasc. Biol. 2010.
24. Wever K.E., Wagener F.A., Frielink C., Boerman O.C., Scheffer G.J., Allison A., Masereeuw R., Rongen G.A. Diannexin protects against renal ischemia reperfusion injury and targets phosphatidylserines in ischemic tissue. PLoS One 2011, 6:e24276.
25. Cheng E.Y., Sharma V.K., Chang C., Ding R., Allison A.C., Leeser D.B., Suthanthiran M., Yang H. Diannexin decreases inflammatory cell infiltration into the islet graft, reduces beta-cell apoptosis, and improves early graft function. Transplantation 2010, 90:709-716.
26. Monraats P.S., Pires N.M., Agema W.R., Zwinderman A.H., Schepers A., de Maat M.P., Doevendans P.A., de Winter R.J., Tio R.A., Waltenberger J., Frants R.R., Quax P.H., van Vlijmen B.J., Atsma D.E., van der L.A., van der Wall E.E., Jukema J.W. Genetic inflammatory factors predict restenosis after percutaneous coronary interventions. Circulation 2005, 112:2417-2425.
27. Sampietro M.L., Pons D., de K.P., Slagboom P.E., Zwinderman A., Jukema J.W. A genome wide association analysis in the GENDER study. Neth. Heart J. 2009, 17:262-264.
28. Lardenoye J.H., Delsing D.J., de Vries M.R., Deckers M.M., Princen H.M., Havekes L.M., van Hinsbergh V.W., van Bockel J.H., Quax P.H. Accelerated atherosclerosis by placement of a perivascular cuff and a cholesterol-rich diet in Apoe*3Leiden transgenic mice. Circ. Res. 2000, 87:248-253.
29. Pires N.M., Schepers A., van der Hoeven B.L., de Vries M.R., Boesten L.S., Jukema J.W., Quax P.H. Histopathologic alterations following local delivery of dexamethasone to inhibit restenosis in murine arteries. Cardiovasc. Res. 2005, 68:415-424.
30. Kemerink G.J., Liu X., Kieffer D., Ceyssens S., Mortelmans L., Verbruggen A.M., Steinmetz N.D., Vanderheyden J.L., Green A.M., Verbeke K. Safety, biodistribution, and dosimetry of 99mTc-HYNIC-annexin V, a novel human recombinant annexin V for human application. J. Nucl. Med. 2003, 44:947-952.